"Questions considered: Does treatment with imatinib mesylate (Gleevec) have palliative benefit, in terms of tumour response, disease progression, survival or quality of life, for patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT tyrosine kinase receptor (identified by CD117 immunohistochemical staining)?"--Guideline review summary.
- Pages
- 38
- Published in
- Ottawa, Ontario
